| Literature DB >> 33161963 |
Elisa Cordero1, Walter Goycochea-Valdivia2, Ana Mendez-Echevarria3, Luis M Allende4, Laia Alsina5, Maria Bravo García-Morato6, Juana Gil-Herrera7, Carlota Gudiol8, Oscar Len-Abad9, Francisco López-Medrano10, David Moreno-Pérez11, Patricia Muñoz12, Peter Olbrich2, Silvia Sánchez-Ramón13, Pere Soler-Palacín14, Clara Aguilera Cros15, Juan Ignacio Arostegui16, Isabel Badell Serra17, Javier Carbone18, Jesús Fortún19, Luis I Gonzalez-Granado20, Eduardo López-Granados21, José Manuel Lucena22, Rocío Parody23, Jan Ramakers24, José R Regueiro25, Jacques G Rivière14, Cristina Roca-Oporto26, Rebeca Rodríguez Pena21, Juan Luis Santos-Pérez27, Carlos Rodríguez-Gallego28, Olaf Neth2.
Abstract
Primary immunodeficiencies (PIDs) are rare, undiagnosed and potentially fatal diseases. Clinical manifestations of PID can be fatal or leave sequelae that worsen the quality of life of patients. Traditionally, the treatment of PIDs has been largely supportive, with the exception of bone marrow transplantation and, more recently, gene therapy. The discovering of new affected pathways, the development of new molecules and biologics, and the increasing understanding of the molecular basis of these disorders have created opportunities in PIDs therapy. This document aims to review current knowledge and to provide recommendations about the diagnosis and clinical management of adults and children with PIDs based on the available scientific evidence taking in to account current practice and future challenges. A systematic review was conducted, and evidence levels based on the available literature are given for each recommendation where available.Entities:
Keywords: Antibiotics; Haematopoietic progenitors transplantation; Primary immunodeficiencies; Treatment; Vaccination
Mesh:
Year: 2020 PMID: 33161963 DOI: 10.1016/j.jaip.2020.05.008
Source DB: PubMed Journal: J Allergy Clin Immunol Pract